NovoCure (NVCR) Operating Expenses (2014 - 2026)

NovoCure (NVCR) has reported Operating Expenses for 13 consecutive years, with $153.0 million the latest figure, recorded in Q2 2026.

• Quarterly Operating Expenses fell 2.43% year-over-year to $153.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $686.7 million (up 4.98% YoY) and the FY2025 annual result came in at $642.3 million, up 0.59% from the prior year.
• Operating Expenses fell to $153.0 million in Q2 2026 per NVCR's latest filing, from $202.5 million in the prior quarter.
• Over the last five years, Operating Expenses for NVCR reached as high as $202.5 million in Q1 2026 and fell as low as $110.6 million in Q1 2022.
• A 5-year average of $153.5 million and a median of $153.0 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 38.14% — and 2025, when it slipped 9.69%.
• Year by year, Operating Expenses stood at $142.5 million in 2022, then climbed by 7.31% to $152.9 million in 2023, then rose by 24.95% to $191.1 million in 2024, then decreased by 9.69% to $172.6 million in 2025, then fell by 11.33% to $153.0 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $153.0 million, $202.5 million, and $172.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.